- Kids’ ER Visits for Injuries Rose During Lockdown, While Non-Injury Cases Fell
- Estrogen Taken During Gender-Affirming Surgeries Won’t Raise Blood Clot Risk: Study
- During Lockdowns, Women Took on Most of Burden of Child Care
- As More Legal Pot Dispensaries Open, More Young Adults Start Using
- Vision Problems? Here’s a Guide to Which Specialist Is Right for You
- Biden Outlines ‘Bold’ National Vaccine Effort
- COVID Pandemic Shortened U.S. Life Expectancy by More Than a Year
- Should Your Child Get a COVID Test?
- AHA News: What Heart and Stroke Patients Should Know About COVID-19 Vaccines
- New Hope Against Diseases Marked by Progressive Scarring of Lung Tissue
Health Highlights: Oct. 4, 2012
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Generic Antidepressant Pulled From Market
A generic version of the popular antidepressant Wellbutrin is being taken off the market after a U.S. Food and Drug Administration analysis showed that it does not work properly.
FDA tests found that the generic drug Budeprion XL 300 released its key ingredient into the blood faster than the brand name drug. The FDA told Teva Pharmaceuticals to withdraw its generic drug, the AP reported.
In 2008, the FDA issued an update that said Budeprion XL 300 and Wellbutrin were essentially the same. That review was conducted after hundreds of patients complained that the generic drug was ineffective or caused side effects such as anxiety, insomnia and headaches.
The FDA’s own study of the generic and brand name drug was completed in August, the AP reported.
